Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial
Vimseltinib was better at shrinking tumors and improving active range of motion, stiffness, pain, and other health measures than the placebo for participants with TGCT. Vimseltinib has the potential to become a new treatment option for patients with TGCT for whom surgery may not provide benefit.
Authors
- Nicholas Matthew Bernthal (ORCID: https://orcid.org/0000-0003-3338-5878)
- Sydney Stern (ORCID: https://orcid.org/0000-0002-1479-605X)
- Jean-Yves Blay
Institutions
- University of California, Los Angeles (US)
- Centre Léon Bérard (FR)
- Patient Advocate Foundation (US)
- Life University (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1080/14796694.2024.2398893
- Citations
- 2
- Primary Topic
- Musculoskeletal synovial abnormalities and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Deciphera Pharmaceuticals